Nakom Mite (Carbidopa, Levodopa)

Levodopa is a precursor that crosses the blood‑brain barrier and is converted into dopamine, directly replenishing the deficient neurotransmitter in Parkinsonian patients. Carbidopa inhibits the peripheral enzyme aromatic L‑amino acid decarboxylase, preventing levodopa from being converted outside the brain, thereby increasing its central availability and reducing peripheral side effects.

The exact dosage of Nakom Mite is individualized and must be determined by a qualified prescriber based on the patient’s clinical condition, response, and tolerability. Physicians typically start with a low dose and adjust gradually to achieve optimal symptom control while minimizing adverse effects.

The safety of carbidopa/levodopa in pregnancy and lactation has not been definitively established. It is classified as pregnancy category unknown, and use should be considered only if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their healthcare provider before using the product.

To place an order, submit an enquiry on the Nakom Mite product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Nakom Mite combines carbidopa with levodopa, offering a balanced approach that maximizes central dopamine production while limiting peripheral side effects. Compared with dopamine agonists, it generally provides stronger symptomatic relief but may be associated with motor complications such as dyskinesia over long‑term use. Choice of therapy depends on disease stage, patient age, and individual response.

Nakom Mite should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the tablets in a dry place and out of reach of children. Do not store in a refrigerator or freezer, as temperature extremes can affect tablet integrity.

Nakom Mite is taken orally, usually with a glass of water. It can be taken with or without food, but high‑protein meals may interfere with absorption, so spacing the dose from protein‑rich meals is often recommended. The prescriber will provide specific instructions on timing and frequency based on the individual treatment plan.

Serious risks include the development of dyskinesia (involuntary movements), psychosis or hallucinations, severe orthostatic hypotension, and rare allergic reactions such as anaphylaxis. Patients should be monitored regularly for these events, and any sudden changes in mood, movement, or cardiovascular status should be reported to a healthcare professional promptly.

Nakom Mite is contraindicated in patients with known hypersensitivity to carbidopa, levodopa, or any excipients in the formulation. It should also be avoided in individuals taking non‑selective MAO inhibitors or those with narrow‑angle glaucoma, malignant melanoma, or a history of severe cardiovascular disease unless specifically directed by a physician.